A NEW DIMENSION TO CANCER CARE

Overcoming Resistance to Cancer Therapy

Deciphering a patient’s unique response to cancer therapy allows us to understand why some treatments help some patients but not others.
Oncohost™ is developing cutting-edge technology to characterize, analyze and predict patient response to treatment. This enables personalized treatment strategies with improved outcomes & reduced side effects.

Introducing the Host Responsetm Profiling PlaTForm

Host Response Profiling is the only system that analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e., the host) in response to a given cancer therapy.
This proteomic profile is highly predictive of individual patient outcome, thus enabling personalized treatment planning. Host Response Profiling also identifies potential drug targets, advancing the development of novel therapeutic strategies.
OncoHost's profiling platform offers a new layer of information, enabling early identification of non-responsiveness to cancer treatments and discovery of new targets to overcome treatment resistance.

Plasma sample
collection

Plasma sample collection

ANTIBODY ARRAY
BASED PROTEOMICS

ANTIBODY ARRAY BASED PROTEOMICS

BIOINFORMATIC
ANALYSIS

BIOINFORMATIC ANALYSIS
    • Differentiating Pathways
    • Protein Correlation Maps
    • Predictive Proteins

 

Host-response
Host-response
identification
characterization
and analysis

Delivering a new standard - All Round Care and Value

Patients

A simple predictive blood test helps your doctor tailor your treatment plan to improve the chance of success

Oncologists

Clinical decision support systems improve patient outcome & reduce unnecessary side effects

Insurers

Identifying appropriate candidates for costly therapies optimizes health coverage plans

Pharma
Companies

Population enrichment improves clinical trial success rate, lowers cost, and enables faster and easier regulatory approval

Investors

Oncohost’s profiling platform provides a versatile and actionable solution for a wide range of cancers and medications, presenting a unique and appealing business proposition

About Oncohost

OncoHost develops personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, we aim to understand the patient's unique response to therapy and overcome one of the major obstacles in clinical oncology today – resistance to therapy.
Based on robust scientific infrastructure and a strong IP position, OncoHost is launching an extensive clinical program with leading
academic and clinical partners.

Our management is comprised of an experienced multi-disciplinary team possessing a unique combination of expertise. With a deep understanding of life sciences and using a systematic approach to understand all biological aspects of disease and medication (tumor and micro-environment), we deliver a new dimension of knowledge to cancer therapy.

Our team & Advisors

OFER SHARON, MD

CEO

MORRIS LASTER, MD

Chairman

YUVAL SHAKED, PH.D.

Co-Founder & Chief Scientist Advisor

DROR YEGER, PHD, MBA

Co-Founder and VP Business Development

ADAM DICKER, MD, PHD

Chief Medical Officer

GIDEON PETROVER, LLB, MBA

COO

ELLA FREMDER, PHD

VP Research and Development

ERAN ISSLER, MSC, MBA

Chief Information Officer

GALIT YAHALOM, PHD

VP Clinical and Regulatory Affairs

SHANI RAVEH SHOVAL, PHD

Intellectual Property Manager

EYAL JACOB, PHD

Pre-clinical Manager

MICHAL HAREL, PHD

Bioinformatics Scientist

NILI DAHAN, PHD

Research Scientist

Scientific Advisory Board

AHARON SCHWARTZ, PH.D.

Head of Advisory Board

RAANAN BERGER, MD/PH.D.

Clinical Advisor

MICHAL LOTEM, MD

Clinical Advisor

IRIT BEN-AHARON, MD, PHD

Clinical Advisor

ORIT KAIDAR-PERSON, MD

Clinical Advisor

ROBERT KERBEL, PHD

Scientific Advisor
X

global summit 12 | 13 march 2020 paris

Contact us

P.O.Box 446, 6 Hamelacha,
Binyamina, Israel
Israel Tel: +972 52 333 5429
Fax: +972 485 37554 E-mail: Ofer@OncoHost.com

TOGETHER, WE UNCOVER A NEW DIMENSION TO CANCER CARE